Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 07/31 04:00:00 pm
135 USD   -0.34%
07/29 VERTEX PHARMACE : reports 2Q loss
07/29 VERTEX PHARMACE : Reports Second Quarter 2015 Financial Results
07/29DJVERTEX PHARMACE : Revenue Rises 20%
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Vertex Pharmaceuticals : SEC Receives Insider Trading Form Involving Vertex Pharmaceuticals

08/01/2015 | 09:42am US/Eastern

Targeted News Service

WASHINGTON, Aug. 1 -- Vertex Pharmaceuticals Inc. [VRTX], Boston, Massachusetts, was involved in the following insider trading activity on a Form 4 filed with the U.S. Securities and Exchange Commission:

INSIDER: Joshua S. Boger

TITLE: Director

DATE RELEASED: July 31, 2015

DATE of ACTION: July 29, 2015

ACTION: Acquired

SHARES: 10,400 shares of common stock at $35.64 per share

ACTION: Disposed

SHARES: 4,000 shares of common stock at $125.71 (2) (3) per share; 5,200 shares of common stock at $127.18 (3) (4) per share; and 1,200 shares of common stock at $127.72 (3) (5) per share

NOW HOLDS: 122,700

EXPLANATION OF RESPONSES:

1. TRANSACTION CODE: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of $125.71 (range $125.43 to $126.35).

3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of $127.18 (range $126.61 to $127.53).

5. Open market sales reported on this line occurred at a weighted average price of $127.72 (range $127.62 to $127.97).

6. DATE EXERCISABLE: Fully vested.

Link: http://www.sec.gov/Archives/edgar/data/875320/000120919115063045/xslF345X03/doc4.xml

Myron Struck, editor, Targeted News Service, Springfield, Va., 703/304-1897; editor@targetednews.com; http://www.targetednews.com

22BalteroF 150801 30FurigayJof-1219287

(c) 2015 Targeted News Service, source News Service

React to this article
Latest news on VERTEX PHARMACEUTICALS INC
08/01 VERTEX PHARMACEUTICALS : SEC Receives Insider Trading Form Involving Vertex Phar..
07/29 VERTEX PHARMACEUTICALS : reports 2Q loss
07/29 VERTEX PHARMACEUTICALS : Reports Second Quarter 2015 Financial Results
07/29DJVERTEX PHARMACEUTICALS : Revenue Rises 20%
07/22 VERTEX PHARMACEUTICALS : to Announce Second Quarter 2015 Financial Results on Ju..
07/15 VERTEX PHARMACEUTICALS : FDA Approves ORKAMBI™ lumacaftor/ivacaftor - the ..
07/15 VERTEX PHARMACEUTICALS : Study Data from Vertex Pharmaceuticals Inc. Provide New..
07/15 VERTEX PHARMACEUTICALS : FDA Greenlights Vertex' ORKAMBI Cystic Fibrosis Medicin..
07/14 VERTEX PHARMACEUTICALS : to Announce Second Quarter 2015 Financial Results on Ju..
07/08 VERTEX PHARMACEUTICALS : Reports Summarize Pharmaceutical and Biomedical Analysi..
Advertisement
Chart
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Income Statement Evolution
More Financials